Brad Perriello, Author at Drug Delivery Business

SteadyMed sets terms for $55m IPO

March 10, 2015 By Brad Perriello

SteadyMed Therapeutics yesterday set the terms for its pending debut on the public market, saying it plans to float 4.25 million shares at $12 to $14 apiece.

Bellerophon prices $60m IPO low, issues more shares

February 13, 2015 By Brad Perriello

Diabetes: Intarcia inks $1B development deal with Servier

November 12, 2014 By Brad Perriello

Intarcia Therapeutics said today that French pharmaceutical independent Servier agreed to a deal to commercialize Intarcia’s implantable diabetes pump that could be worth some $1 billion.

Fresenius ends Russia joint venture, feels impact of Ukraine crisis

November 7, 2014 By Brad Perriello

Shareholders lawsuit against Unilife fizzles

January 23, 2014 By Brad Perriello

The plaintiff in a purported class action shareholders lawsuit against Unilife (NSDQ:UNIS) voluntarily withdrew the complaint after no other stockholders stepped up to join the suit.

pSivida gains big on buyout rumor

June 19, 2013 By Brad Perriello

Shares of ophthalmology company pSivida (NSDQ:PSDV) hit a 52-week high today on speculation from a Seeking Alpha blogger that it’s ripe for an acquisition this year.

PSDV shares hit $3.96 each today, a 52-week high, having gained some 15.5% since a blogger writing as "Bob’s Stocks" published the rumor yesterday.

Baxter buys stake in Ocular Therapeutix

June 10, 2013 By Brad Perriello

Baxter‘s (NYSE:BAX) venture capital arm bought a minority stake in Ocular Therapeutix and its slate of ophthalmic products, part of an $8.5 million funding round that also included existing backer Ascension Health Ventures.